132 related articles for article (PubMed ID: 18953842)
1. [Cetuximab in combination with chemotherapy for patients with gastrointestinal cancer].
Zhang XT; Shen L; Zhang XD; Li J; Zhang ZT
Zhonghua Zhong Liu Za Zhi; 2008 May; 30(5):385-8. PubMed ID: 18953842
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of cetuximab combined with chemotherapy on advanced colorectal cancer: a report of 53 cases].
Guo GF; Xia LP; Zhang B; Jiang WQ; Liu MZ; Hu PL; Chen XX; Qiu HJ; Zhou FF
Ai Zheng; 2009 Dec; 28(12):1317-23. PubMed ID: 19958628
[TBL] [Abstract][Full Text] [Related]
3. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of panitumumab therapy after progression with cetuximab: experience at two institutions.
Saif MW; Kaley K; Chu E; Copur MS
Clin Colorectal Cancer; 2010 Dec; 9(5):315-8. PubMed ID: 21208847
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability.
Lévi F; Karaboué A; Gorden L; Innominato PF; Saffroy R; Giacchetti S; Hauteville D; Guettier C; Adam R; Bouchahda M
Cancer Chemother Pharmacol; 2011 Feb; 67(2):339-48. PubMed ID: 20401611
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
[TBL] [Abstract][Full Text] [Related]
8. [Effect of KRAS mutation on efficacy of Cetuximab combined with chemotherapy in advanced colorectal cancer patients].
Pu XX; Deng YH; Xu F; Xiao J; Guo HQ; Huang H; Tian Y; He YJ; Lin TY
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Nov; 12(6):594-7. PubMed ID: 19921572
[TBL] [Abstract][Full Text] [Related]
9. [Our experience of the treatment with cetuximab for unresectable advanced colorectal cancer].
Yokomizo H; Yoshimatsu K; Osawa G; Matsumoto A; Otani T; Yano Y; Itagaki H; Fujimoto T; Umehara A; Ogawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2249-51. PubMed ID: 21224537
[TBL] [Abstract][Full Text] [Related]
10. [Short-term efficacy of cetuximab combined with radiotherapy or chemotherapy on head and neck cancer: a report of 11 cases].
Xia LP; Zhang B; Liu MZ; Hu PL; Chen XX; Guo GF; Qiu HJ; Rong YM; Qian SY; Zhou FF; Huang YY; Wang TL
Ai Zheng; 2009 Sep; 28(9):977-82. PubMed ID: 19728918
[TBL] [Abstract][Full Text] [Related]
11. [Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Zhang X; Wu Y; Gong J; Lu Z; Zhou J; Wang X; Lu M; Li J; Cao Y; Li Y; Li J; Shen L
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):223-7. PubMed ID: 24785285
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer.
Weickhardt AJ; Price TJ; Chong G; Gebski V; Pavlakis N; Johns TG; Azad A; Skrinos E; Fluck K; Dobrovic A; Salemi R; Scott AM; Mariadason JM; Tebbutt NC
J Clin Oncol; 2012 May; 30(13):1505-12. PubMed ID: 22412142
[TBL] [Abstract][Full Text] [Related]
13. [The efficacy of cetuximab for metastatic colorectal cancer].
Katsumoto Y; Aritake N; Endoh A
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2523-5. PubMed ID: 21224627
[TBL] [Abstract][Full Text] [Related]
14. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Lenz HJ; Van Cutsem E; Khambata-Ford S; Mayer RJ; Gold P; Stella P; Mirtsching B; Cohn AL; Pippas AW; Azarnia N; Tsuchihashi Z; Mauro DJ; Rowinsky EK
J Clin Oncol; 2006 Oct; 24(30):4914-21. PubMed ID: 17050875
[TBL] [Abstract][Full Text] [Related]
15. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B
Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
[TBL] [Abstract][Full Text] [Related]
19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
20. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
